Items-$0.00
Email:sales@ruixibiotech.com
Tel.:02988811435
PF-562771 cas:834894-21-2
PF-562771
| Catalog # | Pkg Size | Price(USD) | Quantity | Buy this product |
|---|---|---|---|---|
| R-C-514 | 50mg | 595.00 | + Add to cart |
|
| R-C-514 | 100MG | 855.00 | + Add to cart |
|
| R-C-514 | 200mg | 1520.00 | + Add to cart |
|
|
|
||||
Product description
AP23464 and PF-562771(AP23848) potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies.Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.
| Appearance | N/A |
|---|---|
| Molecular Weight | N/A |
| Purity | >95% |
| PDI by GPC | <1.5 |
| Solubility | DMSO |
| Storage | -20℃, protected from light and moisture |
| Transportation | 4-25℃ temperature for up to 2 weeks |
| Stability | 1 year |
Document
msds---PF-562771 Related Product
RuixiBiotechCo.Ltd /KamulinBiotechco.ltd
Add: Room 20F 2002, Meiyuan Building, Yanta District, Xi’ an City, Shaanxi Province 710061 China
Tel: 02988811435
Fax: (86-29)8881-1435
Email: sales@ruixibiotech.com
Web: http://www.ruixibiotech.com
